Segall Bryant & Hamill LLC Makes New Investment in Edwards Lifesciences Corporation $EW

Segall Bryant & Hamill LLC acquired a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 1st quarter, HoldingsChannel.com reports. The fund acquired 20,111 shares of the medical research company’s stock, valued at approximately $1,711,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Edwards Lifesciences by 27.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock valued at $9,356,000 after buying an additional 23,514 shares in the last quarter. Sivik Global Healthcare LLC bought a new position in shares of Edwards Lifesciences in the 4th quarter worth about $2,984,000. Norges Bank purchased a new position in Edwards Lifesciences during the 4th quarter valued at about $803,686,000. TD Asset Management Inc lifted its position in Edwards Lifesciences by 6.4% during the 4th quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company’s stock valued at $66,335,000 after acquiring an additional 47,051 shares during the period. Finally, Intech Investment Management LLC boosted its stake in Edwards Lifesciences by 22.2% during the fourth quarter. Intech Investment Management LLC now owns 69,347 shares of the medical research company’s stock worth $5,912,000 after acquiring an additional 12,591 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity

In related news, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $91.70, for a total value of $56,762.30. Following the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,671,117.80. This represents a 1.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the transaction, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. This trade represents a 19.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 43,539 shares of company stock worth $3,685,364 over the last 90 days. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $89.67 on Wednesday. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The company’s 50-day moving average is $88.01 and its 200 day moving average is $83.98. The company has a market capitalization of $51.63 billion, a price-to-earnings ratio of 51.54, a price-to-earnings-growth ratio of 2.23 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.85%. Edwards Lifesciences’s revenue was up 13.6% compared to the same quarter last year. During the same period last year, the business earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Sell-side analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on EW. TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Mizuho lifted their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. UBS Group started coverage on Edwards Lifesciences in a research report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 price target on the stock. Royal Bank Of Canada upped their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Finally, Robert W. Baird raised their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.